Latest filing published 10 Aug 2020 for Cue Biopharma, Inc., €84k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -29.2%Entry US$566.40 · Close at T+365 US$401.10
- +221.4%Entry US$247.20 · Close at T+365 US$794.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Colin Sandercock: trading record in brief
Colin Sandercock discloses dealings in Cue Biopharma, Inc. to SEC (Form 4). The record holds 12 filings, for trades running from 6 June 2019 to 5 August 2020.
The open-market side counts 4 purchases for €223k alongside 4 sales for €562k. On balance, insiders were net sellers of €339k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 4 option exercises. So far in 2020, the count stands at 2 purchases and 4 sales.
In size, the median ticket on the buying side is €59k. 2 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 100% of cases, with a median move of +26.8%. These figures describe past trades and do not predict future prices.
The newest entry dates from 10 August 2020: an option exercise of €84k, in Cue Biopharma, Inc. The last purchase on record was published on 24 February 2020, which is 2,450 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Colin Sandercock
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 13,374 shares@ US$7.509.6% of flowCommon StockSEC:0001209191-20-045921:0
- 13,374 shares@ US$20.0025.7% of flowCommon StockSEC:0001209191-20-045921:1
- 13,274 shares@ US$7.509.6% of flowCommon StockSEC:0001209191-20-045702:0
- 13,274 shares@ US$20.0025.5% of flowCommon StockSEC:0001209191-20-045702:1
- 6,425 shares@ US$7.504.7% of flowCommon StockSEC:0001209191-20-045144:0
- 6,425 shares@ US$20.0012.4% of flowCommon StockSEC:0001209191-20-045144:1
- 201 shares@ US$7.500.1% of flowCommon StockSEC:0001209191-20-045144:2
- 201 shares@ US$20.050.4% of flowCommon StockSEC:0001209191-20-045144:3
- 100 shares@ US$7.350.1% of flowCommon StockSEC:0001209191-20-012027:0Canonical exit: 5 Sept 2019 (T+90)
- 15,025 shares@ US$7.9011.9% of flowCommon StockSEC:0001209191-20-012027:1Canonical exit: 8 Sept 2019 (T+90)
- 2,000 shares@ US$7.101.3% of flowCommon StockSEC:0001209191-19-035958:0Canonical exit: 4 Sept 2019 (T+90)
- 14,938 shares@ US$7.9310.5% of flowCommon StockSEC:0001209191-19-035958:1Canonical exit: 8 Sept 2019 (T+90)
12 of 12 declarations
